AMP And Tilray Are Now Exclusive Partners For Aphria Medical Cannabis Brand
AMP Alternative Medical Products Inc. (Frankfurt: C4TA) (CSE: XCX) announced that it has an exclusive partnership of being the sole marketing partner of Tilray, Inc (NASDAQ |TSX: TLRY). The announcement was made today by AMP through an official press release.
AMP would now be responsible to solely market all Aphria branded cannabis products that are imported or cultivated in Germany.
The supplier of cannabis products for medical purposes functions in accordance with the rules and regulations of BtMG, the German Narcotic Drug Act. The quality of the cannabis products supplied to the pharmacies of Germany remains in line with the standard set by the European Union-Good Manufacturing Practices, also known as EU-GMP.
All the products are supplied to the pharmacies through the wholly-owned subsidiary of AMP. The brand name of the wholly-owned subsidiary is AMP Alternative Medical Products GmbH.
The company runs a podcast titled AMP Roundtable Series. The podcast is telecast publicly. It talks about the issues related to medical cannabis in Germany.
The AMP and Tilray Partnership
AMP published a press release in the media today and announced that it has secured the exclusive partnership rights to be the sole marketer of Aphria branded cannabis products. These products are either cultivated or imported in Germany.
Aphria is known as the global pioneer in the departments of research, cultivation, production, and distribution of cannabis products.
As per the terms and conditions of the agreement, the exclusive partnership relies on the supply and marketing agreement signed between AMP and CC Pharma GmbH. The latter is the wholly-owned subsidiary of Tilray.
At the conclusion of the agreement, AMP can now provide its catalog to German doctors who can refer to it and prescribe the relevant cannabis products to their patients.
The catalog includes a portfolio of a few products. These include Aphria cannabis flowers and extracts with different THC & CBD contents. These products are currently available in the portfolio. In the future, the company is working to cultivate and distribute Aphria medical cannabis flower which would be grown entirely in Germany.
The new product would be grown on behalf of BfArM.
After the conclusion of the agreement, AMP is looking to leverage the wide distribution network of Tilray. It has 13,000 pharmacies spread across Germany. This wide network of distribution would prove to be very beneficial to AMP. This is in addition to the catalog of Aphria branded cannabis products.
Both the partners plan to conduct as many educational seminars as possible. These seminars would be conducted in Germany and they will witness the participation of the doctors. The objective of conducting these seminars is to impart knowledge about their cannabis products. The doctors would, with the help of information shared by the partners, be better able to prescribe the relevant cannabis-based products to their patients.
Doctors would also get updates about any new products the companies come up with in the market.
Dr. Stefan Feuerstein said that the doctors were already aware of their products. The seminars would just highlight the features and benefits of their products in a better manner. Dr. Stefan Feuerstein is the President and Director of AMP.
He added that the exclusive partnership could conclude because of the commitment that AMP shows towards supplying high-quality cannabis products. AMP is also known to have one of the most knowledgeable sales teams that are equipped to pitch all the cannabis products. The company and its sales teams cover not just urban but also small towns & rural regions.